Biotech Correspondent Meghana Keshavan reports on Trinity’s new whitepaper for STAT newsletter, “The Readout.” Learn about the whitepaper’s key findings in Meghana’s article for STAT Plus (subscription required): https://www.statnews.com/2017/05/24/drug-pricing-potential-value/
Trinity Partners today, in tandem with the 22nd Annual International ISPOR Meeting, announced the results of a whitepaper titled, “What We Value: The Proposition Behind the Price.” The authors analyze the costliest drugs to the healthcare system approved by the FDA from 2014-2016 in order to understand the interaction between value and price. In this industry analysis, Trinity reveals the factors that appear to allow some drugs a higher price point than others and addresses key questions including: What do the most expensive drug launches in the recent past reveal about what our society values? What does the market seem to be willing to pay for?
Download the whitepaper here: http://bit.ly/2qQyKso
Managing Partner Dave Fitzhenry recently spoke with PharmaVOICE about the Hepatitis market and what makes it different than other pharmaceutical market landscapes. Learn more about the highly competitive industry here: http://www.pharmavoice.com/article/2017-5-hepatitis
Trinity Partners honored Rare Disease Day on February 28th, a day dedicated to raising awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. We attended several events throughout the country, including MassBio’s Patient Advocacy meeting at the Massachusetts State House and the Metropolitan Hospital Center’s Rare Disease event in New York City. We also tuned into MassBio and ABC News’ Rare Disease Day Tweetchat. Check out a few pictures of our team advocating for the rare disease community!
Trinity Partners today, in concert with the 35th Annual JP Morgan Healthcare Conference, has announced the findings of a white paper exploring the strategic decisions that successfully position a company for a maximized M&A exit. By examining the past ten years of biopharma M&A activity, Trinity has developed a framework that summaries the optimal path for private companies, taking into consideration major factors that inform valuations including financials, R&D portfolio, licensing opportunities, partnerships and more.
Download the whitepaper HERE
Check it out here: http://bit.ly/2foG7PI
The Trinity Alumni Network exists to assist you with staying connected to Trinity, and to each other, wherever you are in your professional development. Join us today by clicking HERE. Trinity provides strategic and tactical insights to address the complex business questions that confront pharmaceutical, biotech, and medical device companies worldwide.
Trinity Partners, a global life sciences consulting firm, announced today that it has welcomed Steve Yonish as an Engagement Manager in its Primary Market Research (PMR) Group. In this new role, Steve will lead engagements for biopharmaceutical clients on topics ranging from market access and reimbursement, pharmaceutical pricing, market/opportunity assessment, brand positioning and more. He will also be responsible for helping to grow Trinity’s Princeton, New Jersey office, which will position Trinity in close proximity to many long-standing clients and will officially open in Summer 2016.
Prior to joining Trinity, Steve was an Associate Partner with BluePrint Research Group where he made significant contributions to business development and led engagements for large-scale global qualitative and quantitative projects across a broad range of therapeutic categories. In addition to his time at BluePrint, Steve has almost twenty years of experience in consultative market research including manufacturing experience with Bristol-Myers Squibb, and market research leadership roles at BioVid Corporation, The Zitter Group, The Monitor Group and Forrester Research. Steve received his BA from Cornell University in Economics, and later received a Ph.D. from the University of Wisconsin in Political Science.
“Steve’s deep industry experience and proven track record of leading strategic initiatives that address a broad range of issues that our clients face make him a perfect addition to our team,” said Neal Dunn, Partner at Trinity Partners. “His hire represents our continued attention to our clients’ primary research needs.”
“I am inspired by the dynamic work that the Primary Market Research group is doing here at Trinity Partners, and I look forward to sharing the knowledge I’ve gained during my time in this industry and collaborating with this talented team.”
Steve’s hire is one of many for Trinity over the past couple of months. Based just outside of Boston, Trinity has over 100 employees with offices in San Francisco and New York City, and was recently named to Consulting Magazine’s list of Fastest Growing Firms as well as The Boston Business Journal’s ‘Best Places to Work’ list. In addition to his regular roles and responsibilities, Steve will participate in the company’s traditional commitment to the development of its young professionals, serving as a mentor to junior colleagues to help improve their writing and strategic thinking skills.
# # #
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click HERE.